文献速递基础与转化研究临床试验与 GCP

吸入300 ppm一氧化氮治疗猪多重耐药铜绿假单胞菌肺炎并在人体中验证安全性

Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans.
PubMed 文献 · Sci Transl Med · 2026-01-21

研究评估吸入300 ppm一氧化氮(iNO300)治疗铜绿假单胞菌(P. aeruginosa)感染的效果与安全性:体外实验显示铜绿假单胞菌对NO供体呈剂量依赖性减少;机械通气猪肺炎模型中,间歇iNO300使细菌负荷下降两个对数、改善氧合与肺顺应性并减轻肺组织病理损伤;10名健康人的1期临床试验未发生不良事件,2例重症监护病房多重耐药菌感染危重患者耐受良好。

要点

  • 体外实验中铜绿假单胞菌对NO供体呈剂量依赖性减少。
  • 猪肺炎模型中间歇iNO300使细菌负荷下降两个对数,并改善氧合与肺顺应性。
  • 10名健康人1期试验未见不良事件;2例危重患者耐受良好,作者认为值得进一步临床评估。

核心结论

  • 作者认为iNO300是有前景的抗铜绿假单胞菌肺炎抗菌手段,值得进一步临床评估。

研究设计与样本

  • 研究包含体外实验、机械通气猪铜绿假单胞菌肺炎模型、10名健康人的1期临床试验,以及2例重症监护病房多重耐药菌感染危重患者的观察。

主要发现

  • 体外实验中铜绿假单胞菌暴露于NO供体后呈剂量依赖性减少。
  • 机械通气猪铜绿假单胞菌肺炎模型中,间歇iNO300治疗使细菌负荷下降两个对数,改善氧合与肺顺应性,并减轻肺组织病理损伤。
  • 10名健康人的1期临床试验确认间歇iNO300治疗安全,无不良事件。
  • 2例重症监护病房多重耐药菌感染危重患者对iNO300耐受良好,显示临床可行性。
  • 对暴露于高剂量iNO超过6年的患者进行长期随访,未发现不良结局。

临床怎么用

  • 作者认为iNO300是有前景的抗铜绿假单胞菌肺炎抗菌手段,值得进一步临床评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO300) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yu B, Safaee Fakhr B, Bry L, et al. Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans. Sci Transl Med. 2026. PMID: 41564156. doi:10.1126/scitranslmed.ady2646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。